March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
FDA Grants Orphan Drug Designation to Umbralisib for Patients with Follicular Lymphoma
March 10th 2020The FDA granted orphan drug designation to umbralisib based on results from the phase IIb UNITY-NHL trial cohort of patients with follicular lymphoma who have received at least 2 prior lines of therapy, including an anti-CD20 monoclonal antibody and an alkylating agent.
Rituximab with BEAM Conditioning Prior to Auto-HCT for DLBCL not Recommended
February 27th 2020This recommendation was based on an analysis of patients with diffuse large B-cell lymphoma undergoing auto-HCT in which the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes.
FDA Grants Priority Review to Tazemetostat for Relapsed/Refractory Follicular Lymphoma
February 14th 2020The submission was primarily based on updated phase II efficacy and safety data for tazemetostat for patients with relapsed or refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy.
Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma
February 8th 2020Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
Phase I Trial Aims to Evaluate Cobomarsen in Certain Hematologic Malignancies
February 4th 2020The phase I trial is evaluating cobomarsen in cancers where the disease process appears to be correlated with an increase in miR-155 levels, including adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
Brentuximab Vedotin with Re-induction Chemotherapy Effective, Well Tolerated in AML
January 3rd 2020A phase I study showed brentuximab vedotin combined with a standard chemotherapy regimen of mitoxantrone, etoposide, and cytarabine may be safe and well tolerated in patients with relapsed/refractory acute myeloid leukemia.
Simon Rule, MD, PhD, on Long-Term Outcomes with Ibrutinib Versus Prior Treatment Regimens
January 2nd 2020The expert hematologist from Plymouth University Medical Center discussed the long-term outcomes of patients receiving ibrutinib for mantle cell lymphoma at the ASH Annual Meeting and Exposition.
Samantha Jaglowski, MD, MPH, Discusses Implications of Tisagenlecleucel for Patients with DLBCL
December 16th 2019The associate professor at The Ohio State University Comprehensive Cancer Center discussed the implications of her analysis of the CAR T-cell therapy tisagenlecleucel for patients with diffuse large B-cell lymphoma at the ASH Annual Meeting & Exposition.
Andre H. Goy, MD, MS, Discusses Extending Survival for Patients with DLBCL
December 13th 2019Andre H. Goy, MD, MS, from Hackensack University Medical Center, discussed ways to address the extension of survival for patients with DLBCL who achieved a complete remission at the ASH Annual Meeting & Exposition.